EP Patent

EP0488959A2 — New uses of competitive NMDA receptor antagonists

Assigned to Novartis Pharma GmbH Austria · Expires 1992-06-03 · 34y expired

What this patent protects

The use of competitive NMDA receptor antagonists in the treatment of withdrawal symptoms in patients undergoing drug withdrawal, for suppression of dependence, habituation or addiction on a dependence-producing drug and for preventing or inhibiting opiate tolerance.

USPTO Abstract

The use of competitive NMDA receptor antagonists in the treatment of withdrawal symptoms in patients undergoing drug withdrawal, for suppression of dependence, habituation or addiction on a dependence-producing drug and for preventing or inhibiting opiate tolerance.

Drugs covered by this patent

donepezil-hydrochloride (DONEPEZIL HYDROCHLORIDE)

Patent Metadata

Patent number: EP0488959A2
Jurisdiction: EP
Classification: —
Expires: 1992-06-03
Drug substance claim: No
Drug product claim: No
Assignee: Novartis Pharma GmbH Austria
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.